Rheumatology News
-
Creative Enzymes Introduces S-Adenosyl-L-Homocysteine Hydrolase, Recombinant
Creative Enzymes, a global leader in enzyme production, is thrilled to announce the latest addition to their hydrolase product line, the Recombinant S-Adenosyl-L-Homocysteine Hydrolase (SAHH). This announcement underscores its unwavering commitment to enzyme innovation and proven track to offering scientifically advanced products. SAHH, a crucial enzyme involved in the biological methylation ...
-
CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI
CD ComputaBio, a reputable computational service provider in the field of biology, has proudly announced the launch of its Antibody De Novo Design technology, marking a pivotal moment in the field of drug discovery and development. This service harnesses the power of AI to engineer antibodies with unmatched precision, paving the way for targeted therapies, personalized medicine, and cutting-edge ...
-
Alfa Chemistry Newly Introduces Three APIs to Meet Market Demands: Tofacitinib Citrate, Tamoxifen Citrate, and Epalrestat
Alfa Chemistry, a leading pharmaceutical supplier, has recently announced the addition of three new APIs to its full-ranged product catalog, i.e., tofacitinib citrate, tamoxifen citrate, and epalrestat. These new products are introduced to meet the growing demands of the pharmaceutical market. Tofacitinib Citrate Tofacitinib Citrate is a medication used to treat rheumatoid arthritis, psoriatic ...
-
Galapagos announces changes to Executive Committee
Dr. Walid Abi-Saab has decided to retire from the company as Chief Medical Officer and member of the Executive Committee, effective 31 December 2022. He will stay with Galapagos until 31 May 2023 to ensure a smooth transition. The company also announces the retirement of André Hoekema who joined Galapagos in 2005 as Chief Business Officer and member of the Executive Committee. Dr. Paul ...
By Galapagos NV
-
Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone
Study evaluating human abuse potential demonstrates that the likeability of cebranopadol administered orally in nondependent recreational opioid users was significantly less as compared to immediate release (IR) formulations of either tramadol or oxycodone, suggesting a lower potential for abuse versus traditional C-II and C-IV opioids A first-in-class investigational analgesic uniquely ...
-
Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted PRAC’s recommendation to add measures to minimise risk of serious side effects with JAK inhibitors for chronic inflammatory disorders. “JAK inhibitors are an important treatment option ...
By Galapagos NV
-
Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022
Galapagos NV (Euronext & NASDAQ: GLPG) will present new data on filgotinib at the American College of Rheumatology (ACR) Convergence 2022 meeting taking place in Philadelphia, Pennsylvania from 10-14 November 2022. Dr. Walid Abi-Saab, Chief Medical officer, at Galapagos said, “We are excited to present data at ACR which highlights our continued commitment to patients and the healthcare ...
By Galapagos NV
-
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
Galapagos NV (Euronext & NASDAQ: GLPG) today held its R&D Day 2022, featuring presentations of key opinion leaders and company management on the strategic, scientific, and commercial progress at the company. The company also presented its financial results for the third quarter of 2022. Paul Stoffels3, CEO and Chairman of the Board of Directors of Galapagos, commented: “Today we ...
By Galapagos NV
-
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
Galapagos NV (Euronext & NASDAQ: GLPG) today announced its strategy for accelerated growth and value creation, its financial results for the first nine months of 2022, and the outlook for the remainder of 2022. The results are further detailed in the Q3 2022 financial report available on the financial reports section of the website. Forward, Faster strategy to accelerate innovation ...
By Galapagos NV
-
GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner, GSK plc (LSE/NYSE: GSK), provided an update on the ContRAst phase III program for otilimab as a potential treatment of moderate to severe rheumatoid arthritis (RA). The ContRAst phase IIl program enrolled a broad range of difficult-to-treat patients who had an inadequate response to or could not tolerate available ...
By MorphoSys AG
-
A new study confirming correlation between Biomechanical Markers and clinical outcomes in knee OA patients
A new study published in BMC Musculoskeletal Disorders confirmed that biomechanical markers are more associated with pain, symptoms and disability compared to imaging findings in knee osteoarthritis patients. Researchers recommend the use of a complementary objective biomechanical evaluation using the KneeKG to conventional imaging to obtain a more complete functional profile of knee OA ...
By Emovi
-
Grossmont Orthopaedic Medical Group Performs First Meniscus Replacement in San Diego with NUsurface Meniscus Implant
Dr. Scott A. Hacker, an expert in arthroscopic surgery, total joint replacements, sports medicine and fracture care, and Active Implants, a company that develops orthopedic implant solutions, today announced that the first meniscus replacement procedure in San Diego has been performed. Dr. Hacker is the only physician in San Diego County – and Grossmont Orthopedic Medical Group is one of ...
-
INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market
INOVIQ (ASX:IIQ) is developing and commercialising next-generation exosome capture tools and precision diagnostics in what CEO Dr Leearne Hinch says is a $15bn medical diagnostics market opportunity for some of the most common – and deadly - cancers. “There’s a clear unmet need for earlier and more accurate cancer diagnostics and INOVIQ is developing a multi-product ...
By INOVIQ Ltd
-
Landmark Survey by Stagwell`s The Harris Poll Estimates More Than 72.3 Million U.S. Adults Suffer from Chronic Low Back Pain - Greater than Arthritis, Diabetes, or Heart Disease and with Debilitating Impact on Quality of Life
Significant Drop in Mobility Due to Chronic Low Back Pain (CLBP) Demonstrated in New Mobility Index, with Highest Drop Among Those in Their 50s Treatment is Deficient with 15% Currently Taking Opioids Despite CDC Guidelines Noting Inadequate Effectiveness and Inherent Risks Only 5% Utilizing Recommended Minimally Invasive Treatment Options The Harris Poll, a Stagwell (NASDAQ: STGW) ...
-
Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, ...
-
What Are D-Glucosamines?
Glucosamine is a natural component of cartilage and is widely used as an over-the-counter nutritional supplement to reduce the pain and cartilage loss of osteoarthritis. Glucosamine is usually taken in combination with chondroitin, which is a glycosaminoglycan that also exists in cartilage.Glucosamine is an amino sugar and an important molecule in the biochemical pathway of glycosylated protein ...
-
Rani Therapeutics Unveils High-Capacity RaniPill Device for Oral Delivery of Biologics
Rani Therapeutics Holdings, Inc. recently announced the development of a high-capacity oral biologics device known as the RaniPill HC (High Capacity), capable of delivering up to a 500%-plus higher drug payload than Rani’s existing oral biologics capsule. In preclinical testing, RaniPill HC demonstrated successful delivery of adalimumab and achieved high bioavailability. “The ...
-
Lazurite™ Named One of the Industry’s Hottest Companies by World’s Largest MedTech Accelerator
MedTech Innovator, the world’s largest accelerator of medical technology companies, yesterday named Lazurite as one of the MedTech industry’s hottest 50 companies by selecting it to participate in Medtech Innovator’s flagship four-month Accelerator program featuring medical device, diagnostic, and digital health technologies from around the globe. As a 2022 Cohort member, ...
-
First tahoe unicompartmental knee system (TUKS) procedure
El Dorado Hills, CA, June 2022 – Shalby Advanced Technologies, (DBA Consensus Orthopedics) proudly reports its first implantation of The Tahoe Uni-compartmental Knee System (TUKS), in Plano,Texas on June 2, 2022. The surgery was performed by Dr. Richard Reitman and was a great surgical success. This surgery marks the culmination of over 6 years of research and development. The patient, a 52 ...
-
Using fungi to slow down cellular ageing
Founded in 2014, KiOmed Pharma is a spin-off of KitoZyme. As explained by François Blondel, Founder and Executive Chairman of the Board of Directors, and Houtai Choumane, CEO of KiOmed Pharma, its aim is to offer solutions to cellular ageing using innovation based on mushrooms. How does your innovation provide a solution for the healthcare sector? François Blondel: ‘We work ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you